The Bio Report

As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including its landmark genetic study of multiple myeloma patients, are helping advance innovative therapies in an area that had long been characterized by its lack of new treatment options. We spoke to Walter Capone, president and CEO of the Multiple Myeloma Research Foundation, about his organization’s efforts, how it’s breaking down barriers to cooperation between its partners, and what it’s doing to get the biggest bang for its research bucks.